Michael B. Sporn

Q: What Schools Are Affiliated With Michael B. Sporn

Michael B. Sporn is affiliated with the following schools: University of Vermont, MD Anderson Cancer Center, University of Michigan, Dartmouth College, Cornell University, Johns Hopkins University, Fudan University

Michael B. Sporn's AcademicInfluence.com Rankings

Michael B. Sporn

Philosophy

#1497

World Rank

#2711

Historical Rank

Logic

#222

World Rank

#475

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Michael B. Sporn's Degrees

Doctorate Medicine Harvard University

Why Is Michael B. Sporn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael B. Sporn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. (1986) (2840)
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. (1993) (2028)
Transforming growth factor beta. (1988) (1883)
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth (1986) (1681)
Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells (1985) (1667)
Can dietary beta-carotene materially reduce human cancer rates? (1981) (1540)
Autocrine growth factors and cancer (1985) (1418)
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. (1983) (1395)
Autocrine secretion and malignant transformation of cells. (1980) (1390)
The Retinoids : biology, chemistry, and medicine (1994) (1377)
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. (1987) (1260)
Some recent advances in the chemistry and biology of transforming growth factor-beta (1987) (1233)
Transforming growth factor-beta: biological function and chemical structure. (1986) (1115)
Peptide Growth Factors and Their Receptors I (1990) (1108)
Type beta transforming growth factor: a bifunctional regulator of cellular growth. (1985) (1066)
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 (1990) (1028)
Expression and secretion of type beta transforming growth factor by activated human macrophages. (1987) (1025)
Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). (1976) (1019)
Transforming Growth Factor‐β (1990) (1002)
Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. (1987) (936)
NRF2 and cancer: the good, the bad and the importance of context (2012) (914)
New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. (1981) (895)
The Transforming Growth Factor-βs (1991) (878)
Recent advances in chemoprevention of cancer. (1997) (861)
Role of retinoids in differentiation and carcinogenesis. (1983) (842)
Cytokines in context (1991) (840)
Deactivation of macrophages by transforming growth factor-β (1988) (838)
Cellular biology and biochem-istry of the retinoids (1984) (831)
Peptide growth factors are multifunctional (1988) (816)
The tumour microenvironment as a target for chemoprevention (2007) (792)
Role of transforming growth factor-beta in the development of the mouse embryo (1987) (769)
Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β) (1993) (755)
Transforming growth factor-beta: recent progress and new challenges (1992) (755)
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. (1992) (751)
Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur (1990) (750)
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. (1986) (708)
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. (1995) (691)
Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex (1990) (657)
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer (2007) (614)
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. (1986) (570)
Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. (2005) (544)
Distribution and modulation of the cellular receptor for transforming growth factor-beta (1987) (540)
A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-β (1988) (535)
Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. (1986) (531)
Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. (1988) (531)
Maternal rescue of transforming growth factor-beta 1 null mice. (1994) (524)
Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro (1987) (519)
Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation (1989) (511)
Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells (1986) (508)
Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. (1989) (504)
Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. (1988) (502)
The war on cancer (1996) (497)
Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice (1989) (455)
TGF-β: Regulation of extracellular matrix (1992) (450)
Approaches to prevention of epithelial cancer during the preneoplastic period. (1976) (448)
Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. (1984) (441)
Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. (1980) (440)
Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. (1994) (429)
Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. (1983) (427)
Mesoderm induction in amphibians: the role of TGF-beta 2-like factors. (1988) (421)
Immunodetection and quantitation of the two forms of transforming growth factor‐beta (TGF‐β1 and TGF‐β2) secreted by cells in culture (1989) (419)
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. (1999) (414)
N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. (1979) (408)
Characterization of the promoter region of the human transforming growth factor-beta 1 gene. (1989) (398)
Purification and initial characterization of a type beta transforming growth factor from human placenta. (1983) (391)
Localization and actions of transforming growth factor-beta s in the embryonic nervous system. (1991) (387)
Cellular transformation by coordinated action of three peptide growth factors from human platelets (1984) (380)
Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. (1992) (376)
Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes (1989) (374)
Chemoprevention: an essential approach to controlling cancer (2002) (368)
Deactivation of macrophages by transforming growth factor-beta. (1988) (366)
Chemoprevention of cancer. (1993) (351)
An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis* (2002) (345)
Targeting Nrf2 with the triterpenoid CDDO- imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice (2009) (340)
Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. (1998) (340)
Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia (2002) (339)
Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease (2012) (339)
Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. (1990) (339)
Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. (2006) (328)
Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. (1989) (327)
Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. (1983) (326)
Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. (1990) (326)
Induction of transforming growth factor-α in activated human alveolar macrophages (1988) (321)
Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. (1989) (319)
Chemoprevention of cancer with retinoids. (1979) (315)
Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system (1991) (306)
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. (1999) (302)
Peptide growth factors and inflammation, tissue repair, and cancer. (1986) (300)
Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. (1990) (297)
Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease (1996) (290)
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. (2011) (282)
Transforming growth factor beta: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. (1988) (276)
New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress (2011) (275)
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes (2006) (273)
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. (2005) (267)
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. (1982) (266)
Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer (2010) (263)
Transforming growth factors from neoplastic and nonneoplastic tissues. (1983) (259)
13-cis-retinoic acid: inhibition of bladder carcinogenesis in the rat. (1977) (255)
Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. (2009) (253)
Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. (2009) (246)
Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). (1993) (245)
Promoter sequences of the human transforming growth factor-beta 1 gene responsive to transforming growth factor-beta 1 autoinduction. (1989) (245)
Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. (2000) (241)
TGF-beta 1 prevents hypertrophy of epiphyseal chondrocytes: regulation of gene expression for cartilage matrix proteins and metalloproteases. (1993) (240)
Colocalization of TGF-beta 1 and collagen I and III, fibronectin and glycosaminoglycans during lung branching morphogenesis. (1990) (238)
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. (2002) (234)
The Transforming Growth Factor‐Betas: Past, Present, and Future (1990) (230)
A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis (1999) (227)
Enhanced expression of transforming growth factor β1 in the rat brain after a localized cerebral injury (1992) (225)
Transforming growth factor-beta. Multiple actions and potential clinical applications. (1989) (224)
Transforming growth factor-β controls receptor levels for epidermal growth factor in NRK fibroblasts (1984) (224)
Complementary deoxyribonucleic acid cloning of a messenger ribonucleic acid encoding transforming growth factor beta 4 from chicken embryo chondrocytes. (1988) (223)
Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. (1994) (220)
Transforming growth factor beta-1 in acute myocardial infarction in rats. (1988) (220)
Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. (1993) (220)
Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. (1990) (214)
Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia (1990) (213)
Hypoxia upregulates the synthesis of tgf-β1 by human dermal fibroblasts (1991) (213)
Effects of Transforming Growth Factor β1, on Scar Production in the Injured Central Nervous System of the Rat (1994) (212)
Transforming growth factor beta (TGF-β) induces fibrosis in a fetal wound model (1988) (212)
Transforming growth factor-beta. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells. (1986) (205)
Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF (1982) (202)
Transforming growth factors. (1985) (200)
Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. (1991) (199)
Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. (2006) (197)
TGF-beta: problems and prospects. (1990) (197)
Transforming growth factor-beta: possible roles in carcinogenesis. (1988) (194)
Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. (1998) (192)
Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. (1994) (191)
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. (2006) (191)
Differential expression of the TGF‐β isoforms in embryogenesis suggests specific roles in developing and adult tissues (1992) (190)
Activation of the second promoter of the transforming growth factor-beta 1 gene by transforming growth factor-beta 1 and phorbol ester occurs through the same target sequences. (1989) (190)
The triterpenoid CDDO induces apoptosis in refractory CLL B cells. (2002) (187)
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. (2002) (187)
Transforming growth factor-beta: multifunctional regulator of differentiation and development. (1990) (183)
NADPH Oxidase Limits Innate Immune Responses in the Lungs in Mice (2010) (181)
A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. (2000) (181)
c-Jun NH2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3,12-Dioxooleana-1, 9-Dien-28-Oate in Human Lung Cancer Cells (2004) (181)
Aflatoxin B1: Binding to DNA in vitro and Alteration of RNA Metabolism in vivo (1966) (179)
Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. (1999) (178)
Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. (2011) (177)
Relationships between structure and activity of retinoids (1976) (177)
Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. (1996) (176)
SEQUENCES OF INTEREST: Complementary Deoxyribonucleic Acid Cloning of a Novel Transforming Growth Factor-β Messenger Ribonucleic Acid from Chick Embryo Chondrocytes (1988) (175)
Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. (1993) (175)
Histogenesis of squamous metaplasia in the hamster tracheal epithelium caused by vitamin A deficiency or benzo[a]pyrene-Ferric oxide. (1972) (174)
Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and Age-related Macular Degeneration (2010) (174)
Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. (1992) (172)
Inhibition of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis by retinyl acetate. (1976) (172)
Autocrine secretion--10 years later. (1992) (171)
Retinyl acetate inhibits mammary carcinogenesis induced by N-methyl-N-nitrosourea (1977) (171)
TGF-beta: regulation of extracellular matrix. (1992) (169)
Identification of a novel transforming growth factor-beta (TGF-beta 5) mRNA in Xenopus laevis. (1990) (166)
Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. (1996) (166)
Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. (2000) (166)
Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). (2001) (164)
Cancer chemoprevention: scientific promise, clinical uncertainty (2005) (164)
Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. (1992) (162)
Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription (2009) (161)
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. (2003) (160)
Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. (1989) (159)
Transforming growth factor-beta. Major role in regulation of extracellular matrix. (1990) (158)
Activity of vitamin A analogues in cell cultures of mouse epidermis and organ cultures of hamster trachea (1975) (158)
The Reversal of an Adriamycin® Induced Healing Impairment with Chemoattractants and Growth Factors (1986) (157)
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. (2010) (156)
Transforming growth factor β levels in rat wound chambers (1987) (155)
Altered expression of transforming growth factor-beta in Alzheimer's disease (1995) (151)
The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. (2007) (150)
Transforming Growth Factor‐&bgr;1 Reduces Infarct Size After Experimental Cerebral Ischemia in a Rabbit Model (1993) (150)
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. (1996) (149)
Structure-activity relationships of retinoids in hamster tracheal organ culture. (1980) (148)
Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. (2007) (148)
Regulation of transforming growth factor beta 1 gene expression by the product of the retinoblastoma-susceptibility gene. (1991) (145)
Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. (2013) (145)
Differential responsiveness of myc- and ras-transfected cells to growth factors: selective stimulation of myc-transfected cells by epidermal growth factor (1986) (144)
Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. (2008) (144)
A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. (2002) (144)
The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Caspase-Dependent and -Independent Apoptosis in Acute Myelogenous Leukemia (2004) (142)
Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. (1985) (140)
Carcinogenesis and cancer: different perspectives on the same disease. (1991) (140)
The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. (2001) (140)
The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. (2000) (137)
Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. (1992) (136)
Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. (1987) (136)
Interleukin-1 stimulates and all-trans-retinoic acid inhibits collagenase gene expression through its 5' activator protein-1-binding site. (1990) (135)
Role of nitric oxide in antagonistic effects of transforming growth factor-beta and interleukin-1 beta on the beating rate of cultured cardiac myocytes. (1992) (135)
Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse (1996) (133)
Complex regulation of TGF beta expression by retinoic acid in the vitamin A-deficient rat. (1991) (132)
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. (2004) (131)
Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. (2005) (131)
Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene (1991) (130)
Characterization of the Promoter Region of the Human Transforming Growth Factor-β Type II Receptor Gene * (1995) (130)
Transcriptional regulation of the transforming growth factor beta 1 promoter by v-src gene products is mediated through the AP-1 complex (1990) (127)
Effects of retinoid deficiency on the development of the heart and vascular system of the quail embryo (1986) (127)
Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-beta. (1989) (126)
Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. (1994) (125)
Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. (2000) (125)
Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin (2009) (124)
Inhibition of mammary cancer by retinyl methyl ether. (1977) (124)
Differential inhibition of transforming growth factor beta 1 and beta 2 activity by alpha 2-macroglobulin. (1990) (123)
Sandwich enzyme-linked immunosorbent assays (SELISAs) quantitate and distinguish two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) in complex biological fluids. (1989) (123)
Retinoids block phenotypic cell transformation produced by sarcoma growth factor (1978) (123)
In vitro metabolism of retinoic acid in hamster intestine and liver. (1979) (123)
Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. (2011) (122)
The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. (1991) (122)
TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. (1993) (121)
Isolation and identification of 4-hydroxy- and 4-oxoretinoic acid. In vitro metabolites of all-trans-retinoic acid in hamster trachea and liver. (1979) (119)
The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. (2003) (118)
Structural and functional characterization of the transforming growth factor beta 3 promoter. A cAMP-responsive element regulates basal and induced transcription. (1990) (117)
Localization of transforming growth factor-beta isotypes in lesions of the human breast. (1992) (115)
Metabolism of all-trans-retinoic acid in hamster liver microsomes: oxidation of 4-hydroxy- to 4-keto-retinoic acid. (1980) (113)
The Synthetic Triterpenoid CDDO-Imidazolide Suppresses STAT Phosphorylation and Induces Apoptosis in Myeloma and Lung Cancer Cells (2006) (112)
13-cis-Retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. (1977) (111)
2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) Directly Targets Mitochondrial Glutathione to Induce Apoptosis in Pancreatic Cancer* (2005) (111)
Antibodies to peptide determinants in transforming growth factor beta and their applications. (1988) (110)
Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. (1994) (108)
MINIREVIEW: Interactions of Retinoids and Transforming Growth Factor-β in Regulation of Cell Differentiation and Proliferation (1991) (106)
Peptide Growth Factors and Their Receptors II (1990) (104)
Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. (1978) (103)
Transforming growth factor‐βs inhibit mitogen‐stimulated proliferation of astrocytes (1993) (103)
Anchorage‐independent growth of primary rat embryo cells is induced by platelet‐derived growth factor and inhibited by type‐beta transforming growth factor (1986) (102)
Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. (2005) (102)
Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL (2003) (102)
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. (2001) (101)
A major advance in the use of growth factors to enhance wound healing. (1993) (101)
Role of transforming growth factor-beta in maintenance of function of cultured neonatal cardiac myocytes. Autocrine action and reversal of damaging effects of interleukin-1. (1992) (101)
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β (2006) (101)
Triterpenoid CDDO‐methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer’s disease (2009) (101)
Transformation of normal rat kidney (NRK) cells by an infectious retrovirus carrying a synthetic rat type alpha transforming growth factor gene. (1987) (100)
Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells. (1983) (100)
Human Immunodeficiency Virus Type 1-Induced Macrophage Gene Expression Includes the p21 Gene, a Target for Viral Regulation (2005) (99)
α and β-Retinyl acetate reverse metaplasias of vitamin A deficiency in hamster trachea in organ culture (1974) (99)
Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter element in PC12 cells. (1994) (99)
Retinoids and carcinogenesis. (2009) (99)
The Novel Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) Potently Enhances Apoptosis Induced by Tumor Necrosis Factor in Human Leukemia Cells* (2002) (98)
Transforming Growth Factor-β1 Circulates in Normal Human Plasma and is Unchanged in Advanced Metastatic Breast Cancer (1995) (98)
The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia reperfusion injury in mice (2013) (97)
Further studies of the role of transforming growth factor-beta in human B cell function. (1989) (96)
Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. (1991) (95)
Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. (1993) (93)
A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. (1999) (92)
Transforming growth factors (TGFs): properties and possible mechanisms of action. (1981) (91)
Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis (2011) (91)
Recombinant TGF-β1 is Synthesized as a Two-Component Latent Complex that Shares Some Structural Features with the Native Platelet Latent TGF-β1 Complex (1989) (90)
Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer (2010) (89)
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. (2017) (88)
Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. (2009) (87)
Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR (2011) (87)
Complementary deoxyribonucleic acid cloning of an mRNA encoding transforming growth factor-beta 2 from chicken embryo chondrocytes. (1990) (87)
A SIMPLE AND RAPID METHOD FOR THE ISOLATION OF ENZYMATICALLY ACTIVE HELA CELL NUCLEI (1969) (86)
Localization of polyadenylic acid sequences in messenger ribonucleic acid of mammalian cells. (1972) (86)
The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection (2008) (86)
Expression of transforming growth factor-beta s 1-4 in chicken embryo chondrocytes and myocytes. (1991) (86)
Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. (2004) (86)
Structure and properties of the cellular receptor for transforming growth factor type beta. (1986) (85)
Induction of transforming growth factor-alpha in activated human alveolar macrophages. (1988) (85)
Induction and autocrine receptor binding of transforming growth factor-beta 2 during terminal differentiation of primary mouse keratinocytes. (1990) (85)
Altered Regulation of TGF‐β1 and TGF‐α in Primary Keratinocytes and Papillomas Expressing v‐Ha‐ras (1991) (85)
Stimulation of DNA synthesis in cultured primary human mesothelial cells by specific growth factors (1988) (84)
Human transforming growth factor-α causes precocious eyelid opening in newborn mice (1985) (84)
Growth factors and transformation. (1986) (83)
Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. (1982) (82)
Mechanism of action of retinoids. (1986) (82)
Vitamin A Deficiency enhances Binding of Benzo(a)pyrene to Tracheal Epithelial DNA (1974) (81)
Transforming growth factor beta. A biologic chorioretinal glue. (1989) (81)
High-pressure liquid chromatographic determination of 13-cis-retinoic acid and all-trans-retinoic acid in human plasma. (1978) (81)
Molecular cloning and structure of the human transforming growth factor-beta 2 gene promoter. (1991) (81)
Differential regulation of the expression of transforming growth factor‐βs 1 and 2 by retinoic acid, epidermal growth factor, and dexamethasone in NRK‐49F and A549 cells (1991) (81)
Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. (2002) (79)
Synthetic Triterpenoids Enhance Transforming Growth Factor β/Smad Signaling (2003) (79)
Secretion and transcriptional regulation of transforming growth factor-beta 3 during myogenesis (1991) (78)
Regulation of the transforming growth factor-β1 and -β3 promoters by transcription factor Spl (1993) (78)
Pharmacological Induction of Heme Oxygenase-1 by a Triterpenoid Protects Neurons Against Ischemic Injury (2012) (77)
N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids. (1981) (77)
The incorporation of 8-azaguanine into rat brain RNA and its effect on maze-learning by the rat: an inquiry into the biochemical basis of memory. (1961) (76)
Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. (1989) (75)
Expression of transforming growth factor-β2 and β3 mRNAs and proteins in the developing chicken embryo (1994) (75)
Localization of transforming growth factor-beta 1 in mitochondria of murine heart and liver. (1991) (74)
Acute ultrastructural effects of benzo[a]pyrene and ferric oxide the hamster tracheobronchial epithelium. (1971) (73)
An element of the transforming growth factor-beta 1 5'-untranslated region represses translation and specifically binds a cytosolic factor. (1993) (73)
Transforming growth factor beta (TGF-beta) induces fibrosis in a fetal wound model. (1988) (73)
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. (2002) (72)
Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. (1995) (72)
A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. (2001) (72)
Retinoid-dependent induction of the in vivo and in vitro metabolism of retinoic acid in tissues of the vitamin A-deficient hamster. (1979) (72)
Mesoderm induction in Xenopus laevis distinguishes between the various TGF-beta isoforms. (1990) (71)
The Multifunctional Nature of Peptide Growth Factors (1991) (71)
THE ISOLATION OF CELL NUCLEI FROM RAT BRAIN (1962) (71)
Nrf2 is a critical modulator of the innate immune response in a model of uveitis. (2009) (71)
Separation of the natural retinoids by high-pressure liquid chromatography. (1978) (70)
Combination chemoprevention of cancer (1980) (69)
The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice (2014) (69)
MOLECULAR THEORIES OF MEMORY. (1964) (69)
The War on Cancer: A Review a (1997) (69)
Genetic changes in the transforming growth factor f8 (TGF-fi) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-, (68)
Transforming Growth Factor-@ in Human Platelets (2011) (68)
Peptide Growth Factors and Inflammation, Tissue Repair, and Cancer (1987) (67)
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. (2006) (66)
Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268 (2008) (66)
Dose-dependent kinetics of all-trans-retinoic acid in rats. Plasma levels and excretion into bile, urine, and faeces. (1981) (66)
Regulation of transforming growth factor-β subtypes by members of the steroid hormone superfamily (1990) (66)
Growth factors and cytokines in health and disease (1997) (66)
Complete Protection against Aflatoxin B1-Induced Liver Cancer with a Triterpenoid: DNA Adduct Dosimetry, Molecular Signature, and Genotoxicity Threshold (2014) (66)
New enone derivatives of oleanolic acid and ursolic acid as inhibitors of nitric oxide production in mouse macrophages (1997) (66)
Induction of nuclear factor-kappa B and the human immunodeficiency virus long terminal repeat by okadaic acid, a specific inhibitor of phosphatases 1 and 2A. (1990) (64)
Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy (2004) (63)
The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. (2009) (63)
In vitro and in vivo metabolism of all-trans- and 13-cis-retinoic acid in hamsters. Identification of 13-cis-4-oxoretinoic acid. (1980) (62)
Cytokines and growth regulation of synoviocytes from patients with rheumatoid arthritis and rats with streptococcal cell wall arthritis. (1990) (62)
Transforming Growth Factor‐β1 in Normal Heart and in Myocardial Infarction (1990) (62)
The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor β-Dependent Apoptosis in Breast Cancer (2004) (61)
Antibodies to transforming growth factor-β2 peptides: Specific detection of TGF-β2 in immunoassays (1990) (61)
Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells (2004) (61)
Pathology of esophageal neoplasms and associated proliferative lesions induced in rats by N-methyl-N-benzylnitrosamine. (1978) (60)
Identification of an activating transcription factor (ATF) binding site in the human transforming growth factor-beta 2 promoter. (1992) (59)
Suppression of carcinogenesis: a role for TGF-beta and related molecules in prevention of cancer. (1990) (59)
Nucleotide synthesis. IV. Phosphorylated 3'-amino-3'-deoxythymidine and 5'-amino-5'-deoxythymidine and derivatives. (1973) (58)
In Vitro Stimulation of Amino-Acid Incorporation into Protein by Liver Nuclear RNA (1962) (57)
Chemical modifications of natural triterpenes - glycyrrhetinic and boswellic acids: evaluation of their biological activity. (2008) (57)
Differential regulation of the expression of transforming growth factor‐β mRNAs by growth factors and retinoic acid in chicken embryo chondrocytes, myocytes, and fibroblasts (1992) (57)
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. (2007) (57)
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities (2007) (57)
Complementary deoxyribonucleic acid cloning of a novel transforming growth factor-beta messenger ribonucleic acid from chick embryo chondrocytes. (1988) (56)
TGF-β: 20 years and counting (1999) (56)
Histopathological evaluation of the inhibition of rat bladder carcinogenesis by 13-cis-retinoic acid. (1977) (56)
Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. (2015) (56)
Binding Affinity of Transforming Growth Factor-β for Its Type II Receptor Is Determined by the C-terminal Region of the Molecule* (1996) (56)
Regulation of collagenase gene expression by okadaic acid, an inhibitor of protein phosphatases. (1990) (56)
The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor–Negative Model of Breast Cancer (2006) (56)
Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice (2009) (55)
The binding of metabolites of aminoazo dyes to rat liver DNA in vivo. (1967) (55)
Retinoids and Chemoprevention of Cancer (1981) (55)
The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent (2007) (55)
NADPH Oxidase and Nrf2 Regulate Gastric Aspiration–Induced Inflammation and Acute Lung Injury (2013) (55)
Antagonistic actions of retinoic acid and dexamethasone on anchorage-independent growth and epidermal growth factor binding of normal rat kidney cells. (1984) (55)
Retinoids increase cell-cell adhesion strength, beta-catenin protein stability, and localization to the cell membrane in a breast cancer cell line: a role for serine kinase activity. (1996) (54)
c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells (2007) (54)
Neuroprotective role of Nrf2 for retinal ganglion cells in ischemia‐reperfusion (2015) (54)
Transforming Growth Factor 81 Positively Regulates Its Own Expression in Normal and Transformed Cells * (2001) (54)
Evidence Supporting a Role for Calcium in Apoptosis Induction by the Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO)* (2004) (52)
Transforming growth factor beta 1: secondary structure as determined by heteronuclear magnetic resonance spectroscopy. (1993) (52)
Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-beta. (1992) (52)
Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. (2003) (52)
Aberrant TGF-β Production and Regulation in Metastatic Malignancy (1990) (52)
The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells (2006) (51)
CDDO-Methyl Ester Delays Breast Cancer Development in Brca1-Mutated Mice (2011) (51)
Role of transforming growth factor-beta isoforms in regulating the expression of nerve growth factor and neurotrophin-3 mRNA levels in embryonic cutaneous cells at different stages of development. (1994) (50)
A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. (2008) (50)
Water deprivation stimulates transforming growth factor-beta 2 accumulation in the juxtaglomerular apparatus of mouse kidney. (1991) (49)
Nucleotide sequence of chicken transforming growth factor-beta 1 (TGF-β 1) (1988) (49)
Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. (2004) (49)
The isolation and physical characterization of nuclear and microsomal ribonucleic acid from rat brain and liver. (1962) (48)
2-Acetamidofluorene and 3-Methylcholanthrene: Differences in Binding to Rat Liver Deoxyribonucleic Acid in vivo (1966) (48)
The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes (2003) (47)
Inhibition of the chondrocyte phenotype by retinoic acid involves upregulation of metalloprotease genes independent of TGF‐β (1994) (47)
Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor beta on endothelial cells. (1992) (46)
ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. (2013) (46)
Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. (2004) (46)
RNA Metabolism in Tracheal Epithelium: Alteration in Hamsters Deficient in Vitamin A (1972) (45)
Nuclear exoribonucleases. III. Isolation and properties of the enzyme from normal and malignant tissues of the mouse (1969) (45)
The role of transforming growth factor‐β1, ‐β2, and ‐β3 in androgen‐responsive growth of NRP‐152 rat prostatic epithelial cells (1998) (45)
The fractionation and characterization of nuclear ribonucleic acid from rat liver. (1963) (45)
Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis. (2014) (44)
Dose-dependent suppression by the synthetic retinoid, 4-hydroxyphenyl retinamide, of streptococcal cell wall-induced arthritis in rats. (1985) (44)
Transcriptional Control of Expression of the TGF‐βs (1990) (44)
Studies on chromatin. II. Effects of carcinogens and hormones on rat liver chromatin. (1966) (44)
Transforming growth factor beta 1: NMR signal assignments of the recombinant protein expressed and isotopically enriched using Chinese hamster ovary cells. (1993) (43)
Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. (2006) (43)
Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats. (1980) (43)
Irreversible Inhibition of Nuclear Exoribonuclease by Thymidine-3'-Fluorophosphate and p-Haloacetamidophenyl Nucleotides (1969) (43)
Anti-angiogenic Activity of a Novel Class of Chemopreventive Compounds: Oleanic Acid Terpenoids (2009) (43)
Actinomycin D and Hydrocortisone: Intracellular Binding in Rat Liver (1965) (42)
Increased expression of growth factor mRNAs accompanies viral transformation of rodent cells. (1988) (42)
Antioxidant vitamins, cancer, and cardiovascular disease. (1996) (42)
Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities (1988) (42)
The Synthetic Triterpenoid CDDO-Methyl Ester Delays Estrogen Receptor–Negative Mammary Carcinogenesis in Polyoma Middle T Mice (2012) (42)
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. (2013) (42)
Roles for transforming growth factors-beta in the genesis, prevention, and treatment of breast cancer. (1992) (41)
Inhibition of urinary bladder cancer by N-(ethyl)-all-trans-retinamide and N-(2-hydroxyethyl)-all-trans-retinamide in rats and mice. (1981) (41)
Transforming growth factor beta levels in rat wound chambers. (1987) (41)
Perspective: The big C — for Chemoprevention (2011) (41)
Histogenesis of induced prostate and seminal vesicle carcinoma in Lobund-Wistar rats: a system for histological scoring and grading. (1994) (41)
Selective inhibition of the anchorage-independent growth of myc-transfected fibroblasts by retinoic acid (1985) (40)
Overexpression of transforming growth factor-beta in transgenic mice carrying the human T-cell lymphotropic virus type I tax gene (1991) (40)
The importance of context in cytokine action. (1997) (40)
Retinyl Acetate: Effect on Cellular Content of RNA in Epidermis in Cell Culture in Chemically Defined Medium (1973) (40)
Purification by reverse-phase high-performance liquid chromatography of an epidermal growth factor-dependent transforming growth factor. (1982) (40)
The early history of TGF-β, and a brief glimpse of its future (2006) (39)
Platforms and networks in triterpenoid pharmacology (2007) (39)
Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. (2008) (38)
Interactions of retinoids and transforming growth factor-beta in regulation of cell differentiation and proliferation. (1991) (38)
Histogenesis of squamous metaplasia and squamous cell carcinoma of the respiratory epithelium in an animal model. (1973) (38)
Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis. (2004) (38)
Ultrastructural effects of N‐methyl‐N‐nitrosourea on the tracheobronchial epithelium of the Syrian Golden hamster (1973) (38)
Comparison of transforming growth factor-beta and a macrophage- deactivating polypeptide from tumor cells. Differences in antigenicity and mechanism of action. (1989) (37)
Prevention of lung cancer in hamsters by 13 CIS retinoic acid (1975) (37)
Clinical Prevention of Recurrence of Colorectal Adenomas by the Combination of Difluoromethylornithine and Sulindac: An Important Milestone (2008) (36)
Induction of transforming growth factor beta in hormonally treated human prostate cancer. (1994) (36)
Characterization of distinct functional domains of transforming growth factor beta. (1993) (36)
Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand. (2007) (36)
Biotransformation and biological activity of N-(4-hydroxyphenyl)retinamide derivatives in rodents. (1981) (35)
Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling. (2004) (35)
Expression of transforming growth factor-beta isoforms in small round cell tumors of childhood. An immunohistochemical study. (1993) (34)
Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle. (1993) (34)
Transforming Growth Factor‐β in Rheumatoid Arthritis (1990) (34)
Sequence-specific 1H-NMR assignments and identification of two small antiparallel beta-sheets in the solution structure of recombinant human transforming growth factor alpha. (1989) (34)
CDDO-Imidazolide Induces DNA Damage, G2/M Arrest and Apoptosis in BRCA1-Mutated Breast Cancer Cells (2011) (34)
Dichotomies in cancer research: some suggestions for a new synthesis (2006) (34)
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis (2008) (33)
Hyperthermia induces expression of transforming growth factor-beta s in rat cardiac cells in vitro and in vivo. (1993) (33)
Assay of retinoids in biological samples by reverse-phase high-pressure liquid chromatography. (1978) (33)
The early history of TGF-beta, and a brief glimpse of its future. (2006) (33)
What is a retinoid? (1985) (32)
Transforming growth factor-βs : chemistry, biology, and therapeutics (1990) (32)
Pattern of expression of transforming growth factor‐β4 mRNA and protein in the developing chicken embryo (1992) (32)
THE SYNTHESIS OF UREA IN THE LIVING RAT BRAIN * (1959) (32)
Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages. (2002) (31)
[Ser77]transforming growth factor-beta 1. Selective biological activity and receptor binding in mink lung epithelial cells. (1994) (31)
Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression (2000) (31)
Sequence specific protein binding to and activation of the TGF-beta 3 promoter through a repeated TCCC motif. (1991) (31)
Transforming Growth Factor‐β: Multifunctional Regulator of Cell Growth and Phenotype (1988) (31)
THE PENETRATION OF PROLINE AND PROLINE DERIVATIVES INTO BRAIN * (1959) (30)
5 – Biological Methods for Analysis and Assay of Retinoids—Relationships between Structure and Activity (1984) (30)
Novel A-ring cleaved analogs of oleanolic and ursolic acids which affect growth regulation in NRP.152 prostate cells (1997) (30)
Potential prophylactic antitumor activity of retinylidene 1,3-diketones. (1980) (30)
Efficient synthesis of (-)- and (+)-tricyclic compounds with enone functionalities in rings A and C. A novel class of orally active anti-inflammatory and cancer chemopreventive agents. (2003) (29)
Activation of nuclear factor E2‐related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development (2008) (29)
Coordinated biochemical and morphologic examination of hamster tracheal epithelium. (1972) (29)
The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid-Imidazolide Alters Transforming Growth Factor β-dependent Signaling and Cell Migration by Affecting the Cytoskeleton and the Polarity Complex* (2008) (29)
Transforming growth factors from a human tumor cell: characterization of transforming growth factor beta and identification of high molecular weight transforming growth factor alpha. (1985) (29)
Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents. (2007) (28)
Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. (2008) (27)
Transforming growth factor alpha: an aromatic side chain at position 38 is essential for biological activity (1989) (27)
Transforming growth factor-beta: Potential common mechanisms mediating its effects on embryogenesis, inflammation-repair, and carcinogehesis (1987) (27)
A New Rexinoid, NRX194204, Prevents Carcinogenesis in Both the Lung and Mammary Gland (2007) (27)
Metabolism of all-trans-retinyl acetate to retinoic acid in hamster tracheal organ culture. (1981) (26)
Regulation of the transforming growth factor-beta 1 and -beta 3 promoters by transcription factor Sp1. (1993) (26)
Isolation and Characterization of TGF-β2 and TGF-β5 from Medium Conditioned by Xenopus XTC Cells (1990) (26)
Dose response to intrarectal administration of N-methyl-N-nitrosourea and histopathologic evaluation of the effect of two retinoids on colon lesions induced in rats. (1978) (26)
Expression of transforming growth factor-beta 2 and beta 3 mRNAs and proteins in the developing chicken embryo. (1994) (26)
Proliferative diseases. (1981) (26)
Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type a and type f 8 transforming growth factors ( soft agar growth / epidermal growth factor / cell transformation / HPLC purification ) (26)
c-Jun NH 2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3 , 12-Dioxooleana-1 , 9-Dien-28-Oate in Human Lung Cancer Cells (2004) (26)
An analytical method for the separation of sugar-methylated ribonucleosides from base-methylated and nonmethylated ribonucleosides. (1972) (25)
NIH deltanoids meeting on Vitamin D and cancer Conclusion and strategic options (2005) (25)
Role for autocrine TGF‐β1 in regulating differentiation of a human leukemic cell line toward osteoclast‐like cells (1994) (25)
Regulation of expression of transforming growth factor-β2 by transforming growth factor-β isoforms is dependent upon cell type (1992) (25)
High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide. (2009) (25)
Metabolism of 13-cis-retinoic acid: identification of 13-cis-retinoyl- and 13-cis-4-oxoretinoyl-beta-glucuronides in the bile of vitamin A-normal rats. (1981) (25)
The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis (2007) (25)
A Synthetic Triterpenoid CDDO-Im Inhibits Tumorsphere Formation by Regulating Stem Cell Signaling Pathways in Triple-Negative Breast Cancer (2014) (25)
Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression (2008) (24)
Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO (2008) (24)
Structure-Activity Relationships in DNA Binding and Nuclear Effects of Aflatoxin and Analogs (1971) (24)
Cervical dysplasia regression induced by all-trans-retinoic acid. (1994) (23)
In vitro metabolism and biological activity of all-trans-retinoic acid and its metabolites in hamster trachea. (1978) (22)
Inhibition of mitogen-induced c-fos expression in melanoma cells by retinoic acid involves the serum response element. (1992) (22)
Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762 (2017) (22)
Observations on the origin and significance of the nuclear envelope-limited monolayers of chromatin unit threads associated with the cell nucleus. (1990) (22)
The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. (1998) (22)
Human transforming growth factor-alpha causes precocious eyelid opening in newborn mice. (1985) (21)
Triterpenoid CDDO-Im downregulates PML/RARα expression in acute promyelocytic leukemia cells (2005) (21)
Is Lycopene an Effective Agent for Preventing Prostate Cancer? (2013) (20)
Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. (2015) (20)
Oral Administration of a Gemini Vitamin D Analog, a Synthetic Triterpenoid and the Combination Prevents Mammary Tumorigenesis Driven by ErbB2 Overexpression (2013) (20)
Cardioprotective actions of transforming growth factor-β. (1993) (20)
Formation of Urea from Arginine in the Brain of the Living Rat (1959) (20)
Synthesis and properties of some 13-cis- and all-trans-retinamides. (1984) (20)
Role of retinoids in differentiation and carcinogenesis. (1984) (19)
Autocrine, paracrine and endocrine mechanisms of growth control. (1985) (19)
The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice (2015) (19)
Alpha- and beta-retinyl acetate reverse metaplasias of vitamin A deficiency in hamster trachea in organ culture. (1974) (19)
A novel low molecular weight ribonucleic acid (RNA) related to transforming growth factor alpha messenger RNA. (1988) (19)
Organ culture of normal and carcinogen-treated rat bladder. (1976) (19)
New Agents for Chemoprevention of Prostate Cancer (1999) (19)
Altered regulation of TGF-beta 1 and TGF-alpha in primary keratinocytes and papillomas expressing v-Ha-ras. (1991) (19)
Is there a common pathway mediating growth inhibition by TGF-beta and the retinoblastoma gene product? (1991) (19)
2-Cyano-3,12-dioxooleana-1,9(11)-diene-28-oic Acid Disrupts Microtubule Polymerization: A Possible Mechanism Contributing to Apoptosis (2006) (19)
Mutational analysis of a transforming growth factor-beta receptor binding site. (1998) (18)
A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice. (2008) (18)
Introduction: What is TGF‐β? (2007) (18)
Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex. (1989) (18)
CDDO-Imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1. (2020) (18)
Localization of benzo(a)pyrene-3H and alterations in nuclear chromatin caused by benzo(a)pyrene-ferric oxide in the hamster respiratory epithelium. (1973) (18)
Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance (2008) (18)
STUDIES ON CHROMATIN. I. ISOLATION AND CHARACTERIZATION OF NUCLEAR COMPLEXES OF DEOXYRIBONUCLEIC ACID, RIBONUCLEIC ACID, AND PROTEIN FROM EMBRYONIC AND ADULT TISSUES OF THE CHICKEN. (1964) (17)
Evidence for Differential Regulation of TGFβ1 and TGFβ2 Expression in Vivo by Sandwich Enzyme‐linked Immunosorbent Assays (1990) (17)
Characterization of mutated transforming growth factor-beta s which possess unique biological properties. (1994) (17)
Transforming growth factor-beta s in mammary tumorigenesis: promoters or antipromoters? (1995) (17)
New Enone Derivatives of Oleanolic Acid and Ursolic Acid as Inhibitors of Nitric Oxide Production in Mouse Macrophages. (1997) (16)
Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer (2004) (16)
Inhibition of transforming growth factor-induced cell growth in soft agar by oxidized polyamines. (1984) (16)
A new kinetic model for polynucleotide metabolism. (1968) (16)
TGF-beta: 20 years and counting. (1999) (16)
Transactivation of the Transforming Growth Factor 01 ( TGF-01 ) Gene by Human T Lymphotropic Virus Type 1 Tax : A Potential Mechanism for the Increased Production of TGF-01 in Adult T Cell Leukemia (2003) (16)
Autoinduction of Transforming Growth Factor 13 Is Mediated by the AP-1 Complex (2003) (16)
Agents for Chemoprevention and Their Mechanism of Action (2003) (16)
Inhibition of RNA-dependent DNA polymerase by thymidylate derivatives. (1972) (15)
Purification of T antigen from nuclei of simian virus 40-induced hamster tumors (1967) (15)
Transforming growth factor-beta: new chemical forms and new biological roles. (1988) (15)
Retinoids and demethylating agents- looking for partners. (2000) (15)
Synergistic increase of phorbol ester-induced c-fos mRNA expression by retinoic acid through stabilization of the c-fos message. (1993) (15)
CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms (2006) (15)
Hobson's choice and the need for combinations of new agents for the prevention and treatment of breast cancer. (2002) (15)
Distribution of acidic fibroblast growth factor, basic fibroblast growth factor, and transforming growth factor β1 in rat growth plate (1990) (15)
Transforming Growth Factor-/ l: Histochemical Localization with Antibodies to Different Epitopes (2002) (14)
Histone and DNA in Isolated Nuclei from Chicken Brain, Liver, and Erythrocytes (1963) (14)
Biological activity and metabolism of the retinoid axerophthene (vitamin A hydrocarbon). (1978) (14)
Rexinoids for prevention and treatment of cancer: opportunities and challenges. (2017) (14)
Retinoids and rexinoids for the 21st century: a brave new world for arthritis. (2003) (14)
The synthesis of phosphorylated 3′-amino-3′-deoxythymidine and 5′-amino-5′-deoxythymidine (1970) (13)
Progress and Perspectives in Chemoprevention of Cancer (1992) (13)
Transforming growth factor-beta and suppression of carcinogenesis. (1989) (13)
Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria (2017) (13)
Transforming growth factor-beta: potential common mechanisms mediating its effects on embryogenesis, inflammation-repair, and carcinogenesis. (1987) (13)
2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. (2010) (12)
Inhibition of 1-methyl-1-nitrosourea-induced mammary carcinogenesis in the rat by the retinoid axerophthene. (1980) (12)
TGF-,B: problems and prospects (12)
Cytokine and Growth Factor Reviews to be published six times a year (2002) (12)
Nucleotide sequence of chicken transforming growth factor-beta 1 (TGF-beta 1). (1988) (11)
Addition of a C-terminal extension sequence to transforming growth factor-beta 1 interferes with biosynthetic processing and abolishes biological activity. (1991) (11)
The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer. (2016) (11)
Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention (2019) (11)
Osteoblasts Synthesize and Respond to Transforming Growth Factor-Type [3 In Vitro (2003) (11)
Quantitation with an automated image analyzer of nuclearcytoplasmic changes induced by hydrocortisone in bladder epithelium. (1977) (11)
Retinoids and cancer prevention. (1979) (11)
Variables in the high-pressure cation-exchange chromatography of proteins. (1982) (10)
Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO). (2014) (10)
Effect of α-Retinyl Acetate on Growth of Hamsters Fed Vitamin A-deficient Diets (1975) (10)
The big C - for Chemoprevention (2011) (10)
Aberrant TGF-beta production and regulation in metastatic malignancy. (1990) (10)
Vitamin A and its analogs (retinoids) in cancer prevention. (1977) (10)
Retinoids and suppression of carcinogenesis. (1983) (10)
Promoter Sequences of the Human Transforming Growth Factor-Bl Gene Responsive to Transforming Growth Factor-/3l Autoinduction” (2001) (10)
Identification and characterization of the chicken transforming growth factor-beta 3 promoter. (1992) (10)
The inauguration of Cytokine & Growth Factor Reviews. (1996) (10)
Inhibition of Growth by Transforming Growth Factor-@ following Fusion of Two Nonresponsive Human Carcinoma Cell Lines (2001) (9)
Transforming growth factors induce markers of neoplasia in cultured adult rat bladder. (1985) (9)
Transforming growth factor-beta 1 modulates calcium metabolism in Sertoli cells. (1993) (9)
Retinoids and cancer prevention. (1979) (9)
Nucleotide synthesis. I. Derivatives of thymidine containing p-nitrophenyl phosphate groups. (1971) (9)
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models (2019) (9)
Interactions of Retinoids and Transforming Growth Factor-Beta in the Chemoprevention of Cancer (1992) (9)
An efficient synthesis of methyl 2-cyano-3,12-dioxoursol-1,9-dien-28-oate (CDDU-methyl ester): analogues, biological activities, and comparison with oleanolic acid derivatives. (2014) (9)
Synthetic triterpenoids, CDDO-Imidazolide and CDDO-Ethyl amide, induce chondrogenesis. (2012) (9)
2'-O-methylation of adenosine, guanosine, uridine, and cytidine in RNA of isolated rat liver nuclei. (1972) (9)
The synthetic triterpenoid TP-222 inhibits RANKL stimulation of osteoclastogenesis and matrix metalloproteinase-9 expression. (2007) (8)
Distinct Regulations of HO-1 Gene Expression for Stress Response and Substrate Induction (2021) (8)
Studies on the effects of chemicals on the processing of nuclear RNA. Some possible implications with respect to carcinogenesis. (1971) (8)
Nucleotide synthesis. Derivatives of thymidine containing m- and p-haloacetamidophenyl phosphate groups. (1972) (8)
Chemical Modifications of Natural Triterpenes—Glycyrrhetinic and Boswellic Acids: Evaluation of Their Biological Activity. (2009) (8)
Transforming growth factor-beta in rheumatoid arthritis. (1990) (8)
Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels. (2008) (7)
Regulation of Cell Differentiation and Proliferation by Retinoids and Transforming Growth Factor β (1990) (7)
Retinoid inhibition of highly invasive urinary bladder carcinomas induced in mice by n-butyl-n-(4-hydroxybutyl)- -nitrosamine (oh-bbn). Abstr. (1980) (7)
Transforming growth factor-beta 1 in normal heart and in myocardial infarction. (1990) (7)
Retraction: The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells. (2004) (7)
Effect of transforming growth factor-beta 1 on myocardial stunning in the intact dog. (1993) (7)
Induction of hyperplasia and its suppression by hydrocortisone in organ-cultured rat urinary bladder. (1977) (7)
Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids. (2017) (7)
Peptide growth factors: current status and therapeutic opportunities. (1987) (7)
Isolation of enzymatically active nuclei from epithelial cells of the trachea. (1971) (7)
Pillars Article: production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986. 163: 1037-1050. (2014) (6)
Retinoids: New Developments in Their Mechanism of Action as Related to Control of Proliferative Diseases (1981) (6)
Regulation of expression of transforming growth factor-beta 2 by transforming growth factor-beta isoforms is dependent upon cell type. (1992) (6)
A new tumor suppressor gene, selective for lung cancer. (2007) (6)
The Reversal of Keratinized Squamous Metaplastic Lesions of Vitamin A Deficiency in Tracheobronchial Epithelium by Vitamin A and Vitamin A Analogs in Organ Culture: A Model System for Anti-Carcinogenesis Studies (1974) (6)
Genetic or Pharmacologic Ampliﬁcation of Nrf2 Signaling Inhibits Acute Inﬂammatory Liver Injury in Mice (2008) (6)
Studies on nuclear exoribonucleases. 3. Isolation and properties of the enzyme from normal and malignant tissues of the mouse. (1969) (5)
Immunohistochemical Localization of TGFβ2 and β3 in the Nervous System (1990) (5)
The synthetic triterpenoid, CDDO-Imidazolide blocks nuclear factor-κB activation through direct inhibition of IκB kinase-beta. (2006) (5)
The E1A oncogene induces resistance to the effects of 1,25-dihydroxyvitamin D3 on inhibition of growth of mouse keratinocytes. (1994) (5)
Introduction: what is TGF-beta? (1991) (5)
Transforming growth factor I81 (TGF-f81) controls expression of major histocompatibility genes in the postnatal mouse: Aberrant histocompatibility antigen expression in the pathogenesis of the TGF-f81 null mouse phenotype (2005) (5)
Transforming Growth Factor β: A Multifunctional Regulatory Peptide with Actions in the Reproductive System (1991) (5)
Studies on the allosteric properties of nuclear exoribonuclease from Ehrlich ascites tumor. (1971) (5)
Chemoprevention of cancer (1978) (5)
Antibodies to transforming growth factor-beta 2 peptides: specific detection of TGF-beta 2 in immunoassays. (1990) (4)
A binding assay for the solubilized receptors of type beta transforming growth factor: adsorption and removal of free ligand by dextran-coated charcoal. (1986) (4)
Chemoprevention, Pharmacology of (2002) (4)
Retinoids and Differentiation of Cells of Mesenchymal Origin (1985) (4)
Human Mammary Epithelial Cells Ursolic Acid Inhibits Cyclooxygenase-2 Transcription in Updated Version (2000) (4)
Structure and function of transforming growth factor-beta. (1986) (4)
Nrf2 protects against radiation-induced oral mucositis via antioxidation and keratin layer thickening. (2022) (4)
Binding of Normal Rat Kidney Cells Anchorage-independent Growth and Epidermal Growth Factor Antagonistic Actions of Retinoic Acid and Dexamethasone on Updated (2006) (3)
Workshop on growth factors. (1991) (3)
DIHYDRORETINOIC ACIDS AND THEIR DERIVATIVES. SYNTHESIS AND BIOLOGICAL ACTIVITY (1977) (3)
Design and Synthesis of Tricyclic Compounds with Enone Functionalities in Ring A and C: A Novel Class of Highly Active Inhibitors of Nitric Oxide Production in Mouse Macrophages (2003) (3)
Cervical Dysplasia Regression Induced by Acid (1994) (3)
Distribution of transforming growth factor beta in a two-week-old human embryo. (1992) (2)
PARP Inhibitors for Chemoprevention—Reply (2014) (2)
Tumor and Stem Cell Biology D Np 63 a-Mediated Activation of BoneMorphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells (2013) (2)
Oncogenes and growth control Edited by P. Kahn and T. Graf. Berlin: Springer-Verlag. (1986). 369 pp. $69.50 (1987) (2)
NRF2 Protects Mice From Cigarette Smoke‐Induced Emphysema (2008) (2)
Efficient Synthesis of (-)- and (+)-Tricyclic Compounds with Enone Functionalities in Rings A and C. A Novel Class of Orally Active Antiinflammatory and Cancer Chemopreventive Agents. (2004) (2)
Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease: (Journal of Neurochemistry (2009) 109 (502-512)) (2009) (2)
A mini-review of chemoprevention of cancer - past, present, and future (2013) (2)
Chemoprevention of Cancer: Past, Present, and Future (2020) (2)
Transforming Growth Factor‐β1 Is Expressed and Synthesized during Fracture Healing (1990) (2)
Effect of alpha-retinyl acetate on growth of hamsters fed vitamin A-deficient diets. (1975) (2)
Apoptosis of Breast Cancer Cells Related Apoptosis-Inducing Ligand to Induce − Factor Synthetic Triterpenoids Cooperate with Tumor Necrosis (2005) (2)
Enhanced Secretion of Activated TGF‐β1 and Post‐Receptor Blockade to TGF‐β1 Signaling in Highly Malignant Fibrosarcomas (1990) (2)
Advances in Brief A Novel Synthetic Oleanane Triterpenoid , 2-Cyano-3 , 12-dioxoolean-1 , 9-dien-28-oic Acid , with Potent Differentiating , Antiproliferative , and Anti-Inflammatory Activity 1 (1999) (2)
Transforming growth factor-beta 1 specifically localizes in elastin during synovial inflammation: an immunoelectron microscopic study. (1990) (2)
Variables in the High-Pressure Cation-Exchange Chromatography of Proteins* (1983) (2)
Detection of Transforming Growth Factor‐β2 and β3 Messenger Ribonucleic Acids in the Chicken (1990) (1)
Control of Growth Factors and Prevention of Cancer (1992) (1)
205 Discovery and Development of Bardoxolone Methyl, an Antioxidant Inflammation Modulator (AIM) Targeting the KEAP1-NRF2 Pathway (2011) (1)
Commentary on Eagle and Foley: "Cytotoxicity in Human Cell Cultures". (2016) (1)
The triterpenoid, CDDO-methyl ester, and the rexinoid, LG100268, synergize in the prevention of mammary tumors in a mouse model of estrogen receptor-negative breast cancer. (2006) (1)
536 POSTER RTA 402 suppresses tumor and treatment induced inflammation, sensitizing tumors to and protecting normal tissue from radiation (2006) (1)
CDDO Increases Translation of CCAAT Enhancer Binding Protein alpha To Induce Granulocytic Differentiation. (2005) (1)
Transforming growth factor-ß: localization and possible functional roles in cardiac myocytes (1993) (1)
in Organ-cultured Rat Urinary Bladder (1977) (1)
Prostatitis and Urethritis (1999) (1)
Abstract 2245: Evaluation of new rexinoids for lung cancer (2017) (1)
Inhibition of Choroidal Neovascularization by the Synthetic Oleanane Triterpenoid CDDO-Im (2011) (1)
Transforming growthfactors: Isolation ofpolypeptides fromvirally andchemically transformed cells byacid/ethanol extraction (sarcoma growth factors/cell transformation/soft agar growth/murine sarcoma virus) (1980) (1)
NRF2 Is Protective In Neutrophil-Mediated Acute Lung Injury (2011) (1)
Abstract 2965: Olaparib and veliparib as effective PARP inhibitors for cancer prevention in a BRCA1-deficient mouse model (2014) (1)
Transforming Growth Factor-fl: Recent Progress and New Challenges (2002) (1)
Abstract A103: The synthetic triterpenoid CDDO-methyl ester targets tumor-associated macrophages to delay carcinogenesis in the PyMT model of estrogen receptor negative breast cancer (2011) (1)
Suppression of carcinogenesis by retinoids: interactions with peptide growth factors and their receptors as a key mechanism. (1985) (1)
Triterpenoids and the rexinoid LG100268 prevent lung tumors induced by vinyl carbamate in strain A/J mice. (2006) (0)
Edward Charles Dodds: diethylstilbestrol. (1983) (0)
Abstract 5559: Novel synthetic pyridyl analogues of CDDO-Im with improved stability and their potential use in cancer prevention (2015) (0)
(TGF-01) Gene by Human T Lymphotropic Virus Type 1 Tax: A Potential Mechanism for the Increased Production of TGF-01 in AdultT Cell Leukemia (1990) (0)
New Approaches to Chemoprevention of Breast Cancer. (1997) (0)
Abstract 293: Therapeutic effects of the bromodomain inhibitors JQ1 and I-BET 762 on pancreatic cancer (2015) (0)
Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria (2017) (0)
SOLUTION STRUCTURE OF TGF-B1, NMR, MODELS 18-33 OF 33 STRUCTURES (1996) (0)
Cyano-substituted oleanolsyrederivater as NO production inhibitors (1999) (0)
Abstract LB-186: The rexinoid LG100268 decreases immunosuppressive immune cells and activates T cells in two preclinical models of breast cancer (2019) (0)
Rese Syn Mou Karen Ralph Abst Intro Ove to be ease i of jus unrese is resi radiot (2010) (0)
Exacerbation of experimental allergic encephalomyelitis by antiserum against transforming growth factor-beta1 (1991) (0)
Abstract A113: Immunomodulatory properties of bromodomain inhibitors in pancreatic cancer cells (2015) (0)
Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor f 3 on endothelial cells ( growth factors / receptors / chimeras ) (0)
Mechanisms and Activity of PPARγ-Active Triterpenoids CDDO and CDDO-Me in Leukemias. (2005) (0)
Abstract 2523: Synthetic triterpenoids protect against toxicity and enhance the efficacy of treatment with carboplatin/paclitaxel in experimental lung cancer (2011) (0)
Tricyclic bisenonderivater and methods of use thereof (2003) (0)
Bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic apoptosis in multiple myeloma (MM) cells (2003) (0)
Antigen driven bystander suppression of acute and relapsing EAE following oral tolerization to MBP: Immunoregulatory pathway dependent on TGF-β (1991) (0)
NUCLEOTID SYNTHESIS PART 4, PHOSPHORYLATED 3′-AMINO-3′-DEOXYTHYMIDINE AND 5′-AMINO-5′-DEOXY-THYMIDINE AND DERIVATIVES (1974) (0)
OMethylation of Adenosine , Guanosine , Uridine , and Cytidine in RNA of Isolated Rat Liver Nuclei (0)
Public Issues Prevention of Cancer in the Next Millennium : Report of the Chemoprevention Working Group to the American Association for Cancer Research 1 , 2 (1999) (0)
thetic Triterpenoids Prolong Survival in a Transgenic Pr R se Model of Pancreatic Cancer (2010) (0)
Abstract 2926: The synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268 extend survival in the KPC transgenic mouse model of pancreatic cancer (2010) (0)
TRANSFORMING GROWTH FACTOR-β EXPRESSION IN NEURODEGENERATIVE DISEASES: 135 (1995) (0)
Peptide hormones. Peptide Hormones as Prohormones: Processing, Biological Activity, Pharmacology. Edited by Jean Martinez. Ellis Horwood, Chichester, 1989. 354pp. £45, $88 (1991) (0)
Cigarette Smoking Induces Ultrastructural Alterations to the RPE in Mice (2008) (0)
Triterpenoids and Prevention of Prostate Cancer (1999) (0)
Abstract LB-245: The EGRF receptor inhibitor Erlotinib, alone or in combination with the rexinoid LG100268, is effective for prevention in mouse models of lung and pancreatic cancer with Kras mutations (2014) (0)
Structure-Activity Relationships of a New Series of Retinoidal Benzoic Acid Derivatives as Measured by Induction of Differentiation of Murine F9 Teratocarcinoma Cells and Human HL-60 Promyelo- cytic Leukemia Cells1 (2006) (0)
Transforming Growth Factor pl : Secondary Structure As Determined by Heteronuclear Magnetic Resonance Spectroscopy + (2001) (0)
D Np63 a -Mediated Activation of Bone Morphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells (2013) (0)
Chemoprevention and Overall Cancer Incidence (2003) (0)
New Triterpenoids for Prevention of Breast Cancer (2002) (0)
A Synthetic Triterpenoid, 2-Cyano-3,12-dioxooleana-1,9-dien-28-oicAcid(CDDO),IsaLigandforthePeroxisomeProliferator-ActivatedReceptor g (2000) (0)
Abstract B105: Inhibition of angiogenesis by oleanoleic acid-derived triterpenoids: mechanisms of action and potential prostate cancer prevention (2008) (0)
Concluding Remarks: Progress in Respiratory Carcinogenesis Bioassays (1974) (0)
癌症化学预防：过去,现在和未来 (2013) (0)
TGF-t 3 Suppresses IL-2-dependent T Cell Proliferation and Partially Inhibits IL-2R and Transferrin Receptor Expression (2003) (0)
Oleanolic acid derivatives substituted with cyano as inhibitors dela NO production. (1999) (0)
Urinary Bladder Cancer in C57BL/6 x DBA/2 FI Mice as a Useful Model for Study of Chemoprevention of Cancer with Retinoids1 (2006) (0)
Retraction notice to "Synthetic triterpenoids, CDDO-Imidazolide and CDDO-Ethyl amide, induce chondrogenesis" [Osteoarthr Cartil 20 (2012) 446-450]. (2020) (0)
System Carcinomas in the Mouse Prostate Reconstitution Model-induced ras + myc Tumor Incidence and the Tumor Mass of Dietary Fenretinide , a Synthetic Retinoid , Decreases the Updated (2007) (0)
Studies on the nuclear exoribonuclease of hela and ehrlich ascites tumor cells. Abstr. (1969) (0)
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models (2019) (0)
5 Chemoprevention as an approach to control of carcinoma of the lung and mesothelioma (2006) (0)
Growth Factor-pl SELECT^ BIOLOGIC^ ACTIVITY AND R E C E ~ O R BINDING IN MINK LUNG E P I ~ E L ~ CELLS* (2001) (0)
Transforming growth factor-(J (TGF-(J) and negative growth control, with special relevance to leukaemia and lymphoma (1991) (0)
Purified transforming growth factor-beta plaques from human placentas and coming. (1984) (0)
Restoration of tissue in animals. (1983) (0)
Abstract 2509: CDDO-Im induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells (2010) (0)
Perspectives in CancerResearch Carcinogenesis and Cancer: Different Perspectives on the Same Disease1 (1991) (0)
News and notices (2005) (0)
Abstract 180: Inhibition of tumorigenesis by a novel Gemini vitamin D analog BXL0124 and a synthetic triterpenoid CDDO-Im in MMTV-HER2/neu transgenic mice. (2013) (0)
Introduction: What is a Retinoid? (2008) (0)
Transcriptionl regulation of TGF-B's 1, 2 and 3 (1990) (0)
BRIEF COMMUNICATION Chemoprevention of Mammary Carcinogenesis in the Rat: Combined Use of Raloxifene and 9-cis-Retinoic Acid (2005) (0)
SYNTHESIS AND PROPERTIES OF SOME 13-CIS- AND ALL-TRANS-RETINAMIDES (1984) (0)
Triterpenoids affect angiogenesis and prevent neoplastic progression (2008) (0)
The king of the hummingbirds, and other tales (1977) (0)
Purification by Reverse-Phase High-Performance Liquid Chromatography of an Epidermal Growth Factor-Dependent Transforming Growth Factor* (1983) (0)
Targeting NLRP3 Inflammasome-Induced Therapy Resistance in ALL (2020) (0)
Novel A‐Ring Cleaved Analogues of Oleanolic and Ursolic Acids Which Affect Growth Regulation in NRP.152 Prostate Cells. (1997) (0)
Angiogenesis as a key target of cancer prevention: The effect of the CDDO-Me triterpenoid (2007) (0)
A Novel Dicyanotriterpenoid, 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, Active at Picomolar Concentrations for Inhibition of Nitric Oxide Production (2002) (0)
Transforming growth factor-,B: possible roles incarcinogenesis* (1988) (0)
POTENTIAL PROPHYLACTIC ANTITUMOR ACTIVITY OF RETINYLIDENE 1,3-DIKETONES (1980) (0)
Abstract A88: The synthetic triterpenoid CDDO-Imidazolide reduces immune cell infiltration and cytokine secretion in the KC mouse model of pancreatic cancer (2016) (0)
SOLUTION STRUCTURE OF TGF-B1, NMR, MINIMIZED AVERAGE STRUCTURE (1996) (0)
Suppression of NMU induced mammary cancer by vitamin A acetate (1977) (0)
Improvements in Airway Hyperresponsiveness and Inflammation in an Asthma Model via Upregulation of Anti-Oxidant Responses with 2-Cyano-3,12-Dioxooleana-1,9 (11)-Diene-28-Oic Acid Trifluoroethyl Amide (CDDO-TFEA) (2008) (0)
Transforming growth factor-beta expression in fibropapillomas induced by bovine papillomavirus type 1, in normal bovine skin, and in BPV-1-transformed cells. (1990) (0)
Advances in Brief Dietary Fenretinide , a Synthetic Retinoid , Decreases the Tumor Incidence and the Tumor Mass of ras + myc-induced Carcinomas in the Mouse Prostate Reconstitution Model System 1 (2007) (0)
Rese Se Syn Mou Karen Ralph Abst Intro Ove to be ease i of jus unrese is resi radiot therap Only (2010) (0)
2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic Acid Anhydride. A Novel and Highly Potent Antiinflammatory and Cytoprotective Agent. (2010) (0)
The synthetic triterpenoid CDDO-Im modulates pathways beyond Keap1-Nrf2 signaling at doses relevant to chemoprevention (2007) (0)
Carcinogenesis ) , GW 7845 , Inhibits Rat Mammary γ ( PPAR-γ Receptor-A New Ligand for the Peroxisome Proliferator-Activated Updated (1999) (0)
Explorer Transcriptional regulation of the AP-1 and Nrf 2 target gene sulfiredoxin (2017) (0)
Nrf2 Signaling Inhibits Pathologic Choroidal Neovascularization (2012) (0)
Perspectives in Cancer Research Role of Retinoids in Differentiation and Carcinogenesis (2006) (0)
Characterization of a Membrane Receptor for Factor-@ in Normal Rat Kidney Fibroblasts* (1984) (0)
Structure-activity relationships in DNA binding and nuclear effects of aflatoxin and anlogs. (1971) (0)
Tackle the Spectrum Of Persistent and Emerging HIV Challenges Seeking a Less Pereect Host Salvage Therapy (2016) (0)
Abstract 820: The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, and the histone deacetylase inhibitor vorinostat delay carcinogenesis in a transgenic model of estrogen receptor-negative breast cancer (2011) (0)
P197 THE EFFECTS OF SYNTHETIC TRITERPENOIDS ON SZP SYNTHESIS IN ARTICULAR CHONDROCYTES (2006) (0)
Vitamin A and cancer (1984) (0)
Overexpression of Bcl-3 sustains MMP-1 expression against inhibition by CDDO in SW-1353 cells (2011) (0)
Transforming growth factor-beta — mediator of carcinogenesis, inflammation and embryonic development (1988) (0)
Abstract LB-265: Comparison of oleanane triterpenoids and dimethyl fumarate in lung cancer (2015) (0)
Targeting Nrf2 with a Small Molecule Approach Attenuates Cigarette Smoke-Induced Emphysema and Cardiac Dysfunction in Mice. (2009) (0)
Review and Introductory Remarks: The Role of Organ Culture and Cell Culture Methods in Studies of Respiratory Carcinogenesis and Anti-Carcinogenesis (1974) (0)
Type fl transforming growth factor: A bifunctional regulator of (2016) (0)
Perspectivesin CancerResearch Carcinogenesis and Cancer : Different Perspectives on the Same Disease 1 (2006) (0)
Transforming growthfactor type,8: Rapidinduction offibrosis and angiogenesis invivoandstimulation ofcollagen formation invitro (1986) (0)
The combination of triterpenoids and rexinoids for the prevention of experimental lung cancer (2007) (0)
A novel synthetic tricyclic compound with an acetylene group at C-8a and cyano enones in rings A and C is a potent multifunctional agent in vitro and suppresses the formation of aflatoxin-DNA adducts in vivo (2007) (0)
Transforming growth factor-beta in the developing embyro (1989) (0)
Abstract LB-344: The rexinoid LG100268 modulates immune cell populations in mammary gland tumors of MMTV-neu mice (2018) (0)
Treatment and Prevention of Intraepithelial Neoplasia : An Important Target for Accelerated New Agent Development Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia 1 (2002) (0)
Comparison of the rexinoids Bexarotene and Pyrimidine‐Bexarotene in a preclinical model of lung carcinogenesis (2017) (0)
The SyntheticTriterpenoid CDDO-Imidazolide Suppresses STAT Phosphorylation and Induces Apoptosis in Myeloma and Lung Cancer Cells (2006) (0)
Type f 8 transforming growth factor : A bifunctional regulator of cellular growth ( growth inhibitor / anchorage-independent growth / human tumor cells / epidermal growth factor ) (0)
Vol. 35, 1999 (1999) (0)
FUTURE ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (2017) (0)
Thesis Abstracts, 1995 (1995) (0)
Abstract PP01-01: Chemoprevention of Cancer: Past, Present, and Future (2013) (0)
Transforming Growth Factor Pl: NMR Signal Assignments of the Recombinant Protein Expressed and Isotopically Enriched Using Chinese Hamster Ovary Cells7 (2001) (0)
Abstract B76: Synthetic triterpenoids as candidate drugs for cancer prevention and treatment (2011) (0)
Subject Index Vol. 35, 1999 (1999) (0)
Rexinoid LG100268 affects angiogenesis in vitro and in vivo (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael B. Sporn?

Michael B. Sporn is affiliated with the following schools: